You are viewing an incomplete version of our website. Please click to reload the website as full version.

CD13 antibody (Alanyl (Membrane) Aminopeptidase) (PerCP)

Details for Product anti-ANPEP Antibody No. ABIN1043023, Supplier: Log in to see
Antigen
  • Apn
  • pepN
  • SC8E4A.13
  • APN
  • CD13
  • GP150
  • LAP1
  • P150
  • PEPN
  • AP-M
  • AP-N
  • Cd13
  • Apm
  • KZP
  • Lap1
  • rAPN
  • APDE
  • p150
Reactivity
Human, Non-Human Primate
316
87
15
12
8
8
7
5
3
Host
Mouse
273
67
62
2
2
Clonality (Clone)
Monoclonal ()
Conjugate
This CD13 antibody is conjugated to PerCP
64
52
28
18
3
2
2
2
2
2
2
2
1
1
1
1
1
1
1
Application
Functional Studies (Func), Immunohistochemistry (Frozen Sections) (IHC (fro)), Flow Cytometry (FACS), Immunoprecipitation (IP)
275
110
66
63
55
48
36
30
22
9
8
5
3
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Immunogen Human AML cells
Clone WM15
Isotype IgG1
Specificity The antibody WM15 recognises the human CD13 cell surface glycoprotein, a 150 kDa molecule expressed on granulocytes, endothelial cells, epithelial cells and myeloid progenitors.HLDA III, WS Code M 213HLDA IV, WS Code M 44HLDA IV, WS Code M 209HLDA V, WS Code M MA191
Characteristics The purified antibody is conjugated with Peridinin-chlorophyll-protein complex (PerCP) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use.
Alternative Name ANPEP (ANPEP Antibody Abstract)
Background CD13 (aminopeptidase N, APN) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyzes removal of neutral amino acids from small peptides, thus activating or inactivating bioactive peptides. CD13 has also role in extracellular matrix degradation, antigen processing and signal transduction, is important in inflammatory responses, regulates intercellular contact, cell motility and vascularization. CD13 is involved in protection of leukemic cells against apoptosis and its expression associated with poor prognosis of carcinomas.
Gene ID 290
Pathways
Application Notes The reagent is designed for Flow Cytometry analysis of human blood cells using 10 µL reagent / 100 µL of whole blood or 10^6 cells in a suspension. The content of a vial (1 mL) is sufficient for 100 tests.

Working concentrations should be determined by the investigator.
Comment

CD Antigens & MHC (Veterinary), CD and Related Antigens (Human)

Restrictions For Research Use only
Reconstitution No reconstitution is necessary.
Buffer The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2 % (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.
Preservative Sodium azide
Precaution of Use WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
Handling Advice Do not freeze.
Avoid prolonged exposure to light.
Storage 4 °C
Storage Comment Store in the dark at 2-8 °C. Do not use after expiration date stamped on vial label. Short-term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.
Supplier Images
Flow Cytometry (FACS) image for anti-CD13 antibody (Alanyl (Membrane) Aminopeptidase)  (PerCP) (ABIN1043023) Surface staining of human peripheral blood leukocytes with anti-CD13 mouse monoclonal...
Product cited in: McCormack, Muji?, Osdal et al.: "Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia." in: Blood, Vol. 121, Issue 7, pp. e34-42, 2013 (PubMed).

Favaloro, Browning, Facey: "CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated." in: Experimental hematology, Vol. 21, Issue 13, pp. 1695-701, 1993 (PubMed).

Bradstock, Favaloro, Kabral et al.: "Myeloid progenitor surface antigen identified by monoclonal antibody." in: British journal of haematology, Vol. 61, Issue 1, pp. 11-20, 1985 (PubMed).

Bradstock, Favaloro, Kabral et al.: "Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells." in: Pathology, Vol. 17, Issue 3, pp. 392-9, 1986 (PubMed).

Background publications Terauchi, Kajiyama, Shibata et al.: "Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells." in: BMC cancer, Vol. 7, pp. 140, 2007 (PubMed).

Petrovic, Schacke, Gahagan et al.: "CD13/APN regulates endothelial invasion and filopodia formation." in: Blood, Vol. 110, Issue 1, pp. 142-50, 2007 (PubMed).

Tokuhara, Hattori, Ishida et al.: "Clinical significance of aminopeptidase N in non-small cell lung cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 13, pp. 3971-8, 2006 (PubMed).